Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Non-cash Items (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Non-cash Items data on record, last reported at $2.7 million in Q3 2025.

  • For Q3 2025, Non-cash Items rose 29.49% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $2.7 million, up 29.49%, while the annual FY2024 figure was $2.1 million, 85.8% down from the prior year.
  • Non-cash Items reached $2.7 million in Q3 2025 per CTNM's latest filing, up from $2.6 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $14.9 million in Q4 2023 and bottomed at $1.9 million in Q2 2024.
  • Average Non-cash Items over 3 years is $3.8 million, with a median of $2.2 million recorded in 2024.
  • Peak YoY movement for Non-cash Items: plummeted 85.8% in 2024, then skyrocketed 35.87% in 2025.
  • A 3-year view of Non-cash Items shows it stood at $14.9 million in 2023, then tumbled by 85.8% to $2.1 million in 2024, then surged by 30.01% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $2.7 million in Q3 2025, $2.6 million in Q2 2025, and $2.2 million in Q1 2025.